| abstract |
The present invention relates to novel pyrrolopyrimidine compounds of formula (I) wherein R 1 , R 2Y , R 4 , R 8 -R 11 , A and L are as defined herein, and salts thereof, including pharmaceutically acceptable salts. The compounds of the present invention are CDK4/6 inhibitors and are useful in the treatment of diseases and disorders mediated by CDK4/6, such as cancer, including mantle cell lymphoma, liposarcoma, non-small cell lung cancer, melanoma, squamous cell esophagus cancer and breast cancer. The invention also relates to pharmaceutical compositions comprising the compounds of the invention. The invention also relates to methods of inhibiting CDK4/6 activity and the use of compounds of the invention or pharmaceutical compositions comprising compounds of the invention for the treatment of disorders associated therewith. |